Loading company…
Rappta Therapeutics develops PP2A-targeting cancer drugs intended to reactivate a key tumor suppressor.
Founded in 2019 and based in Helsinki, Finland, Rappta Therapeutics is a biopharmaceutical company developing drugs involving protein phosphatase 2A (PP2A) to reactivate a key tumor suppressor.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in